BSE: 526853 | NSE: | Plastic Products | Small Cap
Past 10 year’s financial track record analysis by Moneyworks4me indicates that Bilcare Ltd is a below average quality company.
The key valuation ratios of Bilcare Ltd's currently when compared to its past seem to suggest it is in the Somewhat Undervalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Bilcare Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | -4.1% | -11.2% | -0.6% | -3.2% | -20.5% | -6.4% | 7.6% | 6.1% | 87.5% | 1.9% | - |
| Value Creation Index ⓘ | -1.3 | -1.8 | -1.0 | -1.2 | -2.5 | -1.5 | -0.5 | -0.6 | 5.3 | -0.9 | - |
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ | |||||||||||
| Sales ⓘ | 331 | 315 | 286 | 258 | 240 | 212 | 304 | 430 | 14 | 17.6 | 17 |
| Sales YoY Gr. | - | -4.8% | -9.5% | -9.8% | -6.9% | -11.7% | 43.6% | 41.3% | -96.8% | 25.9% | - |
| Adj EPS ⓘ | -78.2 | -29.7 | -49 | -106.7 | -133.3 | -50 | -9.8 | -19.5 | 14.5 | -2.6 | -2.2 |
| YoY Gr. | - | NA | NA | NA | NA | NA | NA | NA | NA | -118% | - |
| BVPS (₹) ⓘ | 283.3 | 264.4 | 236.3 | 202.4 | 68.6 | 25.1 | 25.8 | 18.4 | 174.3 | 176.5 | 176.1 |
| Adj Net Profit ⓘ | -184 | -69.8 | -115 | -251 | -314 | -118 | -23.1 | -45.8 | 34.2 | -6.1 | -5 |
| Cash Flow from Ops. ⓘ | -16.7 | 28.4 | 37.3 | 7.2 | 62.1 | 71.1 | -0.4 | 46.3 | 397 | 97.6 | - |
| Debt/CF from Ops. ⓘ | -69 | 34.3 | 24.1 | 119.4 | 14 | 10 | -1642.7 | 14.9 | 0 | 0.1 | - |
CAGR Colour Code Guide ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | -27.8% | -40.7% | -61.3% | 25.9% | ||||
| Adj EPS ⓘ | NA | NA | NA | -118% | ||||
| BVPSⓘ | -5.1% | 20.8% | 89.9% | 1.3% | ||||
| Share Price | 3.8% | 29.7% | -1.9% | -11% | ||||
Performance Ratio Colour Code Guide ⓘ
| Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | -24.2 | -10.8 | -19.6 | -48.6 | -98.4 | -106.7 | -38.6 | -88 | 15.1 | -1.5 | -1.3 |
| Op. Profit Mgn % ⓘ | 6.4 | 8.6 | -1 | 0.4 | 0.8 | -2.6 | 8.3 | 8.6 | -37.2 | -51.3 | -54.1 |
| Net Profit Mgn % ⓘ | -55.6 | -22.1 | -40.4 | -97.5 | -130.9 | -55.6 | -7.6 | -10.7 | 244.8 | -34.9 | -30.7 |
| Debt to Equity ⓘ | 1.7 | 1.6 | 1.6 | 1.8 | 5.4 | 12 | 11.2 | 15.9 | 0 | 0 | 0 |
| Working Cap Days ⓘ | 592 | 448 | 278 | 290 | 300 | 346 | 273 | 229 | 5,522 | 1,820 | 1,192 |
| Cash Conv. Cycle ⓘ | 212 | 140 | 61 | 64 | 53 | 36 | 40 | 52 | 1,079 | 94 | 784 |
Sales growth is good in last 4 quarters at 10.68%
Return on Equity is Poor
Sales growth has been subdued in last 3 years -61.32%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | -2.2 | -17.1 |
| TTM Sales (₹ Cr.) | 17 | 771 |
| BVPS (₹.) ⓘ | 176.1 | 202.1 |
| Reserves (₹ Cr.) ⓘ | 391 | 452 |
| P/BV ⓘ | 0.40 | 0.35 |
| PE ⓘ | 0.00 | 0.00 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 51.00 / 95.40 |
| All Time Low / High (₹) | 5.00 / 1830.00 |
| Market Cap (₹ Cr.) | 166 |
| Equity (₹ Cr.) | 23.6 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 41.1 |
| Pledged * | 1.39 | 1.39 | 1.39 | 0.00 | 1.39 | 1.39 | 1.39 | 1.39 | 1.39 | 1.39 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 331 | 315 | 286 | 258 | 240 | 212 | 304 | 430 | 14 | 18 |
| Operating Expenses ⓘ | 310 | 300 | 288 | 258 | 240 | 219 | 279 | 393 | 21 | 27 |
| Manufacturing Costs | 15 | 13 | 21 | 21 | 22 | 21 | 30 | 36 | 1 | 4 |
| Material Costs | 241 | 222 | 212 | 183 | 169 | 143 | 190 | 288 | 5 | 9 |
| Employee Cost | 24 | 27 | 29 | 29 | 29 | 27 | 32 | 34 | 6 | 6 |
| Other Costs ⓘ | 31 | 39 | 27 | 25 | 20 | 28 | 27 | 35 | 9 | 8 |
| Operating Profit ⓘ | 21 | 15 | -3 | 0 | 0 | -8 | 25 | 37 | -7 | -9 |
| Operating Profit Margin (%) | 6.3% | 4.8% | -1.0% | -0.1% | 0.0% | -3.6% | 8.3% | 8.5% | -51.1% | -51.8% |
| Other Income ⓘ | 4 | 11 | 5 | 14 | 7 | 14 | 14 | 16 | 4 | 9 |
| Interest ⓘ | 132 | 32 | 48 | 56 | 72 | 69 | 75 | 68 | 0 | 2 |
| Depreciation ⓘ | 106 | 101 | 79 | 304 | 248 | 88 | 35 | 35 | 5 | 2 |
| Exceptional Items ⓘ | 0 | -117 | 68 | 246 | 0 | 24 | 52 | 27 | 511 | 11 |
| Profit Before Tax ⓘ | -212 | -223 | -56 | -101 | -314 | -127 | -18 | -24 | 503 | 6 |
| Tax ⓘ | -28 | -145 | 10 | -21 | 1 | -24 | -19 | -6 | 112 | 0 |
| Profit After Tax | -184 | -78 | -66 | -80 | -315 | -102 | 2 | -18 | 391 | 5 |
| PAT Margin (%) | -55.5% | -24.8% | -23.1% | -31.0% | -131.0% | -48.3% | 0.6% | -4.1% | 2,794.6% | 30.3% |
| Adjusted EPS (₹) | -78.1 | -33.2 | -28.0 | -34.0 | -133.0 | -43.5 | 0.8 | -7.6 | 166.0 | 2.3 |
| Dividend Payout Ratio (%) | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | ||||||||||
| Shareholders Fund | 667 | 623 | 556 | 477 | 161 | 59 | 61 | 43 | 410 | 416 |
| Share Capital ⓘ | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves ⓘ | 643 | 599 | 533 | 453 | 138 | 36 | 37 | 20 | 387 | 392 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt | 1,151 | 976 | 898 | 857 | 868 | 709 | 678 | 690 | 8 | 9 |
| Long Term Debt | 949 | 773 | 714 | 702 | 714 | 559 | 530 | 537 | 8 | 9 |
| Short Term Debt | 202 | 203 | 184 | 155 | 153 | 150 | 149 | 153 | 0 | 0 |
| Trade Payables | 26 | 47 | 50 | 57 | 72 | 51 | 61 | 79 | 6 | 2 |
| Others Liabilities ⓘ | 778 | 342 | 426 | 165 | 213 | 69 | 24 | 3 | 36 | 33 |
| Total Liabilities ⓘ | 2,623 | 1,988 | 1,931 | 1,555 | 1,314 | 887 | 823 | 816 | 460 | 460 |
Fixed Assets | ||||||||||
| Gross Block | 1,596 | 1,568 | 1,587 | 1,587 | 1,585 | 1,586 | 901 | 909 | 31 | 78 |
| Accumulated Depreciation | 379 | 392 | 440 | 743 | 991 | 1,079 | 429 | 463 | 15 | 15 |
| Net Fixed Assetsⓘ | 1,217 | 1,177 | 1,147 | 844 | 594 | 506 | 473 | 446 | 16 | 63 |
| CWIP ⓘ | 125 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investmentsⓘ | 682 | 553 | 553 | 514 | 513 | 173 | 89 | 81 | 294 | 294 |
| Inventories | 142 | 52 | 30 | 25 | 32 | 22 | 44 | 56 | 1 | 1 |
| Trade Receivables | 73 | 60 | 49 | 41 | 37 | 39 | 72 | 93 | 9 | 5 |
| Cash Equivalents | 17 | 11 | 6 | 3 | 7 | 5 | 8 | 5 | 12 | 2 |
| Others Assetsⓘ | 368 | 135 | 146 | 128 | 131 | 141 | 136 | 136 | 128 | 96 |
| Total Assets ⓘ | 2,623 | 1,988 | 1,931 | 1,555 | 1,314 | 887 | 823 | 816 | 460 | 460 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ | -17 | 28 | 37 | 7 | 62 | 71 | 0 | 46 | 397 | 98 |
| PBT ⓘ | -184 | -223 | -124 | -346 | -314 | -151 | -70 | -51 | -8 | -5 |
| Adjustment ⓘ | 207 | 252 | 128 | 286 | 321 | 352 | 136 | 93 | 390 | 11 |
| Changes in Working Capital ⓘ | 17 | -0 | 35 | 69 | 56 | -130 | -68 | 5 | 17 | 91 |
| Tax Paid ⓘ | -1 | 0 | -1 | -1 | -1 | -1 | 1 | -1 | -1 | 1 |
| Cash Flow From Investing Activity ⓘ | -14 | 9 | -48 | 78 | 2 | 11 | 85 | 6 | 181 | -107 |
| Capex | -17 | 0 | -50 | -1 | 1 | 0 | 1 | -1 | 394 | -108 |
| Net Investments | 1 | 8 | 0 | 1 | 1 | 11 | 84 | 7 | -213 | 0 |
| Others ⓘ | 2 | 1 | 1 | 78 | 0 | 0 | 0 | 0 | 0 | 1 |
| Cash Flow From Financing Activityⓘ | 23 | -35 | 6 | -87 | -60 | -83 | -82 | -55 | -571 | -1 |
| Net Proceeds from Shares ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Proceeds from Borrowing ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Paid ⓘ | 0 | 0 | -48 | -56 | -72 | -69 | -75 | -68 | 0 | -2 |
| Dividend Paid ⓘ | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Others ⓘ | 23 | -35 | 54 | -31 | 12 | -14 | -8 | 13 | -570 | 2 |
| Net Cash Flow ⓘ | -9 | 2 | -5 | -1 | 3 | -1 | 2 | -4 | 7 | -10 |
| PARTICULARS | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | -24.15 | -12.13 | -11.18 | -15.48 | -98.82 | -92.77 | 2.98 | -34.16 | 172.22 | 1.29 |
| ROCE (%) | -4.11 | -11.22 | -0.56 | -3.23 | -20.49 | -6.4 | 7.58 | 6.06 | 87.45 | 1.94 |
| Asset Turnover Ratio | 0.13 | 0.15 | 0.16 | 0.15 | 0.17 | 0.19 | 0.36 | 0.52 | 0.02 | 0.04 |
| PAT to CFO Conversion(x) | N/A | N/A | N/A | N/A | N/A | N/A | 0 | N/A | 1.02 | 19.6 | Working Capital Days |
| Receivable Days | 98 | 72 | 64 | 62 | 59 | 66 | 67 | 70 | 1,332 | 149 |
| Inventory Days | 141 | 105 | 48 | 38 | 44 | 46 | 40 | 43 | 745 | 14 |
| Payable Days | 44 | 60 | 84 | 107 | 140 | 156 | 107 | 88 | 3,116 | 171 |
Bilcare, incorporated in the year 1987, is engaged in manufacturing pharmaceutical packaging. It has an experience of working with 500 pharma manufacturing companies worldwide.Bilcare is a global leader and an innovation-led packaging solutions provider that partners with the pharmaceutical industry to improve patient healthcare outcomes. The company endeavor to deliver effective and affordable solutions that enhance the speed and quality of drug discovery and help build and protect brands by ensuring the delivery of genuine medicines to patients.
Bilcare PPI offers Innovative Pharmaceutical Packaging Solutions comprising of a wide range of specialty Polymer Films and Aluminum Foils mainly used for packaging of solid dosage pharmaceutical products.
Bilcare GCS provides Global Clinical Material Supplies for new drug discovery projects.
Bilcare Technologies provides Anti-counterfeit (ncID - nonclonableID) solutions for product & people ID authentication and security
The company develops design keeping various aspects into consideration such as end-user, optimum material, composite dosages, on-pack communication, cost-effective, regulatory requirements, etc.It also offers pharmaceutical research and clinical services.
It has representative offices located in
It maintains quality standards prescribed by various agency such USFDA, DEA, IQA, SAP, ISO 9001 and 14001.Bilcare has a global customer base and customers comprise many of the largest global pharmaceutical companies viz. Bristol-Myers Squibb, Dr. Reddy’s, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Ranbaxy, Sanofi-Aventis, Teva to name a few. Bilcare has a strong customer base of over 2,500 customers in over 50 countries worldwide.
For packaging purposes the company uses material like blister films range, aluminium foils, cold formed blisters, wrap systems, closures & containers, flexibles and eco-friendly paper composites.
Bilcare Singapore Pte a wholly owned subsidiary acquired 100 percent stakes in Singapore-based Singular ID. The firm specialises in technology to identify fake drugs.
In 2010 Bilcare won Pharmexcil / Govt of India Patent Award-2009-10.
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
